Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure drug vericiguat put to the test in small trial

NCT ID NCT05420012

Disease control Sponsor: Josef Stehlik Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 4 trial tested whether vericiguat, a drug already approved for heart failure, can improve blood vessel function, reduce inflammation, and enhance quality of life in 26 people with heart failure with reduced ejection fraction. Participants received either vericiguat or a placebo, and researchers measured changes in artery dilation, walking distance, and symptom scores. The study aims to identify which patients might benefit most.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vericiguat (Verquvo)
What this could lead to
If successful, vericiguat could become a new option to improve blood vessel health and quality of life for people with heart failure.
What could go wrong
This is a small, early-phase trial with only 26 participants, so results may not apply broadly. The drug may not show meaningful benefits over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

26 people

The number who actually took part.

Started

May 2023

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of chronic symptomatic HF (ACC/AHA Class C) and New York Heart Association (NYHA) Class II or III symptoms at the time of enrollment. * Left ventricular ejection fraction (LVEF) of ≤45% assessed within 12 months prior to randomization by any imaging method. * Systemic blood pressure ≥90/60 mmHg. * Standard guideline-directed HF therapy. * If female of reproductive potential, agrees to avoid becoming pregnant while receiving study drug and for 14 days after the last dose of study drug by complying with abstinence from heterosexual activity or use (or have her partner use) contraception during heterosexual activity. Exclusion Criteria: * Addition of a new disease-modifying HF pharmacotherapy or CRT-D in previous 4 weeks. * Current or anticipated use of long-acting nitrates or nitric oxide (NO) donors including isosorbide dinitrate, isosorbide 5-mononitrate, pentaerythritol tetranitrate, nicorandil or transdermal nitroglycerin (NTG) patch, and molsidomine. * Current or anticipated use of phosphodiesterase type 5 (PDE5) inhibitors such as vardenafil, tadalafil, and sildenafil. * Current use or anticipated use of a soluble guanylate cyclase (sGC) stimulator such as riociguat. * Known allergy or sensitivity to any sGC stimulator. * Estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m2 or chronic dialysis. * Patients who are pregnant or breastfeeding or plan to become pregnant or to breastfeed.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Heart failure with reduced ejection fraction (hfref)

Contacts and locations

Locations

  • University of Utah Hospital

    Salt Lake City, Utah, 84132, United States

  • Veterans Affairs Salt Lake City Health Care System (VAMC)

    Salt Lake City, Utah, 84148, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.